Human Genome to lay off 97 workers

Company acquired by GlaxoSmithKline in process of integrating workforce with corporate parent

October 17, 2012|By Gus G. Sentementes, The Baltimore Sun

Human Genome Sciences Inc., which was acquired for $3.6 billion by London-based GlaxoSmithKline Plc in August, intends to lay off 97 employees in mid-December, and an additional but unspecified number of cuts are planned for next year, the company warned Maryland labor regulators this week.

The Rockville-based biopharmaceuticals company, which employed as many as 1,000 people up until the acquisition, is in the process of integrating with GSK, a spokesman said.

Previously, the company disclosed in September it would cut 114 positions by the end of this month. A third round of cuts are planned for early next year, but the company did not disclose a precise figure to the Maryland Department of Labor, Licensing and Regulation, which tracks mass layoffs among employers in the state.

Gus.sentementes@baltsun.com

Twitter.com/gussent

Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.